Alterity Therapeutics to Present at MST Financial Webinar
Alterity Therapeutics (NASDAQ: ATHE), a biotechnology company focused on developing treatments for neurodegenerative diseases, has announced an upcoming investor webinar.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alterity Therapeutics (NASDAQ: ATHE), a biotechnology company focused on developing treatments for neurodegenerative diseases, has announced an upcoming investor webinar. The event, hosted by MST Financial, is scheduled for July 25, 2024, at 8:30 AM AEST (July 24, 2024, at 6:30 PM ET).
CEO David Stamler will present recent company developments, including interim data from the Phase 2 open-label study of ATH-434 (202). Investors and shareholders can register for the Zoom webcast and will have the opportunity to ask questions following the presentation.
This webinar provides a platform for Alterity to share its progress in developing disease-modifying treatments and engage with its investor community.
Details
News Market Reaction – ATHE
The recorded move for ATHE in the trading session of this news was -2.15%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MELBOURNE, Australia and SAN FRANCISCO, July 24, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be presenting a webinar to investors and shareholders hosted by MST Financial on Thursday, 25 July 2024 at 8:30am AEST. CEO David Stamler will present the Company’s recent developments, including the recently announced interim data for the Phase 2 open-label study of ATH-434 (202).
Details are listed below:
Webcast details
AUSTRALIA PARTICIPANTS:
| Date: | Thursday, 25 July 2024 | ||
| Time: | 8:30 a.m. AEST (Sydney/Melbourne) | ||
UNITED STATES PARTICIPANTS:
| Date: | Wednesday, 24 July 2024 | ||
| Time: | 3:30 p.m. Pacific Time | ||
| 6:30 p.m. Eastern Time | |||
Register for the Zoom webcast:
https://mstfinancial-au.zoom.us/webinar/register/WN_8zfACjD8TqO7SsMcAyxzkg
Registration is required and dial in details will be sent directly upon registration.
Investors will have the opportunity to ask questions during the call, at the conclusion of the presentation.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Hannah Howlett
we-aualteritytherapeutics@we-worldwide.com
+61 450 648 064
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.